Literature DB >> 29038824

Memantine add-on to clozapine treatment for residual negative symptoms of schizophrenia.

Selene Veerman1, Peter Schulte2, Lieuwe de Haan3.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29038824     DOI: 10.1007/s00213-017-4756-9

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


× No keyword cloud information.
  4 in total

Review 1.  Understanding controlled trials. Crossover trials.

Authors:  B Sibbald; C Roberts
Journal:  BMJ       Date:  1998-06-06

2.  Memantine add-on to antipsychotic treatment for residual negative and cognitive symptoms of schizophrenia: a meta-analysis.

Authors:  Taro Kishi; Yuki Matsuda; Nakao Iwata
Journal:  Psychopharmacology (Berl)       Date:  2017-05-15       Impact factor: 4.530

3.  Adjunctive memantine in clozapine-treated refractory schizophrenia: an open-label 1-year extension study.

Authors:  S R T Veerman; P F J Schulte; J B Deijen; L de Haan
Journal:  Psychol Med       Date:  2016-10-25       Impact factor: 7.723

4.  Memantine augmentation in clozapine-refractory schizophrenia: a randomized, double-blind, placebo-controlled crossover study.

Authors:  S R T Veerman; P F J Schulte; J D Smith; L de Haan
Journal:  Psychol Med       Date:  2016-04-06       Impact factor: 7.723

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.